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Abstract Peptic digestion of bovine hemoglobin yields a
fragment with antibacterial activity. This peptide was purified
to homogeneity by a two-step procedure including anion exchange
chromatography and preparative reversed-phase HPLC. Mass
determination and fragmentation indicated that this peptide
corresponded to the 1^23 fragment of the K chain of hemoglobin.
The minimum inhibitory concentration and mode of action of this
peptide towards Micrococcus luteus strain A270 were deter-
mined. Hemolytic assay, interaction with liposomes, and study of
its structure in solution were also performed. ß 2001 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
For many years, protein hydrolysates derived from di¡erent
sources of agricultural proteins (soya, casein, wheat, or ¢sh)
have been used as food ingredients [1]. Additional applica-
tions such as nutritional therapy [2], stimulating e¡ects on
fermentation [3], immunostimulating properties [4], or biolog-
ical activities such as antimicrobial activities have also been
investigated. Antibacterial activities of hydrolysates derived
from bovine [5] or human [6] lactoferrin, bovine K-casein
[7], bovine K-lactalbumin [8], or bovine chroma⁄n granules
[9] have been described.
Bovine hemoglobin has also been used as a substrate to
obtain organoleptic and bioactive peptides by enzymatic hy-
drolysis such as a bitter peptide [10] or a bacterial growth-
stimulating peptide [11]. Hemoglobin has also been described
as a source of endogenous bioactive peptides [12]. Recently,
the antibacterial activity of a peptide was found in the gut of
the tick Boophilus microplus [13]. This peptide, corresponding
to the 33^61 fragment of the K chain of bovine hemoglobin,
was most potent against Micrococcus luteus A270, a bacterial
strain commonly used as a sensitive strain for the detection of
antibiotic substances [14].
In our laboratory, di¡erent peptides have already been ob-
tained from peptic hydrolysis of bovine hemoglobin. Thus, a
bradykinin-potentiating peptide [15,16], opioid peptides [17],
or amphiphilic peptides used in photochemotherapy for their
ability to solubilize and carry protoporphyrin IX in solution
[18] have been described for medical applications to deliver
hydrophobic photosensitizers to tumor tissues [19].
Among these amphiphilic peptides, the 1^23 fragment of
the K chain of bovine hemoglobin, which is an e⁄cient carrier
of the porphyrin, is easily and rapidly puri¢ed in large quan-
tities [20]. This K 1^23 fragment was tested for its antibacterial
activity towards M. luteus A270. The present paper is the ¢rst
report on the antibacterial activity of a peptide isolated from
a peptic bovine hemoglobin hydrolysate.
2. Materials and methods
2.1. Preparation and puri¢cation of the K 1^23 peptide
Bovine hemoglobin hydrolysate was obtained as a powder on a
pilot-plant scale by pepsin proteolysis in an ultra¢ltration reactor
followed by decolorization (removing of heme) with MgO, desalting
and atomization, as previously described [21].
The K 1^23 peptide was puri¢ed by the method previously proposed
[20] and slightly modi¢ed.
Anion exchange chromatography was performed using a 380 ml Q-
Sepharose Fast Flow gel (Bio Process Medium) in a XK 50 column
(Pharmacia; 300U50 mm). 475 mg of peptic hydrolysate dissolved in
10 ml of 50 mM ethanolamine^HCl bu¡er, pH 10.5, was applied to
the column previously equilibrated with the same bu¡er. After a 300
ml wash, elution was performed with the same bu¡er containing dif-
ferent NaCl concentrations: 600 ml bu¡er (25 mM NaCl), 1350 ml
bu¡er (45 mM NaCl), and then 300 ml bu¡er (1 M NaCl) to clean
and regenerate the column. The £ow rate was 5 ml/min. Detection of
peptides was done at 280 nm. Five runs in a row were performed and
fractions corresponding to the di¡erent peaks were collected and kept
at 4‡C. Fractions containing the K 1^23 peptide were then pooled,
desalted by a pilot-plant electrodialysis apparatus as previously de-
scribed [20], and lyophilized. The peptide powder was then dissolved
in 2 ml distilled water and peptides were separated by preparative
reversed-phase (RP) HPLC. The apparatus was a Waters 600E
pump system controller connected to a LC spectrophotometer
(Waters) set at 226 nm and separation was performed using a prep-
arative Waters C18 column (300U19 mm). The mobile phase was
water/tri£uoroacetic acid (1000:1, v/v) as eluent A and acetonitrile/
water/tri£uoroacetic acid (600:400:1, v/v) as eluent B. The gradient
applied was linear from 3 to 25% B over 10 min and from 25 to 30%
B over 80 min. The £ow rate was 13.6 ml/min and two injections of
1 ml each were performed. Each fraction was manually collected and
lyophilized. Purity was checked by mass spectrometry and analytical
RP-HPLC.
2.2. Purity of the peptide
Mass determination was performed by matrix-assisted laser desorp-
tion ionization mass spectrometry (MALDI-MS) with a Finnigan Mat
Vision 2000 time-of-£ight mass spectrometer equipped with a viewing
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unit. All data were acquired at 500 MHz sampling frequency in re-
£ectron mode with external and/or internal calibration and also in
linear mode. The nitrogen laser spot size was 70 Wm and the laser
energy was adjusted close to threshold. The following matrix was
used: a mixture of 2,5-dihydroxybenzoic acid (12 g/l) and 2-hy-
droxy-5-methoxybenzoic acid (12 g/l) (9:1, v/v) was prepared with
acetonitrile/water (1:2, v/v) as solvent. A 1 Wl portion of the matrix
solution was mixed with 0.5 Wl of sample solution on a stainless steel
target, dried in a gentle stream of air and loaded into the mass spec-
trometer. Mass spectra were obtained preferably from the crystalline
rim of the dried sample. Usually, 15^30 spectra were averaged in
linear mode and 20^40 in re£ectron mode. Linear con¢guration was
used applying 30 keV ion energy for the re£ectron time-of-£ight ana-
lyzer, 5 keV ion energy and 20 keV post-acceleration to a discrete
dynode secondary electron multiplier in positive ion mode.
The analytical RP-HPLC system consisted of a Waters 600E auto-
mated gradient controller pump module, a Waters Wisp 717 auto-
matic sampling device and a Waters 996 photodiode array detector.
Spectral and chromatographic data were stored on a NEC image 466
computer. Millennium software was used to plot, acquire, and analyze
chromatographic data. All the chromatographic processes were per-
formed with an analytical Vydac C4 column (250U4.6 mm). The
mobile phase was water/tri£uoroacetic acid (1000:1, v/v) as eluent A
and acetonitrile/water/tri£uoroacetic acid (600:400:1, v/v) as eluent B.
The £ow rate was 1 ml/min. Samples were ¢ltered through 0.22 Wm
¢lters and then injected. The gradient applied was 0^67% (v/v) B over
30 min then 67^87% (v/v) B over 35 min. On-line UV absorbance
scans were performed between 200 and 300 nm at a rate of one
spectrum per second with a resolution of 1.2 nm. Chromatographic
analyses were completed with Millennium software.
2.3. Bacterial strain, culture media and antimicrobial assays
M. luteus A270 was used as the test microorganism for determina-
tion of antibacterial activity. The strain was conserved at 324‡C in
glycerol-containing nutrient broth and was subcultured twice in Mul-
ler^Hinton broth (Biokar Diagnostics) under agitation (60 rpm) at
30‡C before use.
Antibacterial activity of the peptide was evaluated by a liquid
growth inhibition assay. For determination of the minimum inhibitory
concentration (MIC), the strain was cultured in a series of tubes con-
taining 1 ml of Muller^Hinton broth with various concentrations of K
1^23 peptide (1.5 Wg/ml^1.5 mg/ml). A standard inoculum of 16 h
culture cells was added to each tube at a ¢nal concentration of
1U106 CFU/ml. The MIC was taken as the lowest concentration of
peptide that caused 100% growth inhibition after 24 h of incubation at
30‡C under agitation at 60 rpm. For bactericidal activity assay, a
suspension of M. luteus strain A270 corresponding to the MIC tube
after 24 h of incubation was serially 10-fold diluted in tryptone salt
solution and plated onto Petri plate count agar (15 g/l) for CFU
determination. Incubation of plates was for 72 h at 30‡C.
2.4. Hemolytic assay
The hemolytic activity of the peptide was determined using bovine
erythrocytes by methods previously proposed [9,22], slightly modi¢ed.
After isolation of the erythrocytes by centrifugation (1000Ug for
5 min), they were washed three times with 10 mM sodium phosphate,
pH 7.5, containing 0.9% NaCl (NaCl/Pi). The cell concentration stock
suspension was adjusted to 1U109/ml. The cell suspension (12.5 Wl),
varying amounts of peptide stock solution (10 mg/ml in NaCl/Pi), and
NaCl/Pi were pipetted into Eppendorf tubes to give a ¢nal volume of
50 Wl. The suspension containing 2.5U108 cells/ml was then incubated
for 40 min at 37‡C. After centrifugation (1000Ug for 5 min), 30 Wl of
supernatant was diluted in 500 Wl water. The absorbance of the di-
luted solution was measured at 420 nm. The absorbances obtained
after treating erythrocytes with only NaCl/Pi and 0.2% SDS were
taken as 0% and 100%, respectively.
2.5. Liposome preparation and liposome content leakage
Lipid ¢lms were obtained by evaporating a solution of lipid in
chloroform (phosphatidyl ethanolamine (1 mg), phosphatidyl glycerol
(0.3 mg) and cardiolipin (0.15 mg)). The lipids were then hydrated in
1 ml Tris^HCl bu¡er (20 mM, pH 7.0) containing carboxy£uorescein
(100 mM) by vortex-mixing for 10 min. The solution was readjusted
to pH 7.0 with NaOH (1 M). The suspension was freeze-thawed for
¢ve cycles and then successively extruded ¢ve times though a poly-
carbonate ¢lter (0.1 Wm pore size). Then, carboxy£uorescein-contain-
ing liposomes were subjected to gel ¢ltration (Sephadex G75, 200U10
mm) ion Tris^HCl bu¡er. Two peaks were collected: the ¢rst one
corresponded to the liposomes and the second one to the free carboxy-
£uorescein. The lipid concentration was determined by phosphorus
analysis [23].
Tris^HCl bu¡er (20 mM, pH 7.0) was added to the liposome sus-
pension so that the ¢nal concentration of lipids was 2.5 mM. Peptide
solutions (25, 37.5, and 50 WM) were added to the diluted liposomal
suspension (3 ml). Thus, lipid/peptide ratios were 100:1, 67:1 and
50:1, respectively. Carboxy£uorescein was excited at 470 nm and
the emission was monitored between 450 and 700 nm with a £uores-
cence spectrophotometer (Perkin Elmer LS 50B). The percentage of
dye leakage (PDL) induced by the peptide was evaluated using the
equation PDL = [(F3F0)/(Ft3F0)]U100, where F is the £uorescence
intensity after the addition of the peptide, and F0 and Ft are the
£uorescence intensity without the peptide before and after addition
of Triton X-100 (2 g/l), respectively. Triton X-100 was used to release
completely the dye from the liposomes (100% dye leakage).
2.6. Structure of the peptide in solution
The aggregation state of the peptide was studied by UV spectro-
photometry (280 nm). The absorbance of various solutions of the
peptide (0^300 WM) in ammonium acetate bu¡er (10 mM, pH 7)
was recorded. Then, separation of the peptide was performed by ex-
clusion chromatography. The column used, Superdexpeptide HR
10/30 (Pharmacia; 300U10 mm), was calibrated with: serum albumin
(67 000 Da), A chain of bovine insulin (2531 Da), angiotensin II
(1046 Da), L-NAD (663 Da), and glutathione (307 Da). 50 Wl of
peptide at a concentration of 10 mg/ml was applied. The bu¡er was
ammonium acetate bu¡er (10 mM, pH 7) and the £ow rate was 0.5
ml/min.
Infrared spectra were realized with a Bru«cker IFS-48 spectrometer,
after drying the solution of peptides on silica chips. A spectrum rep-
resents the accumulation of 200 recordings with a resolution of
4 cm31 in the range 4000^400 cm31. Spectra in Fourier transform
were obtained by means of the standard Bru«cker software and inter-
preted according to previous papers [24,25]. Three concentrations of K
1^23 peptide were tested, 1.25, 2.5, and 5% (w/v), in ammonium
acetate bu¡er (20 mM, pH 7.0).
3. Results and discussion
3.1. Isolation of the peptide
Chromatography used in this study was developed in two
steps to obtain a su⁄cient quantity of the K 1^23 peptide in
order to study its biological activity and its structure in solu-
tion.
After the ¢rst step of bovine hemoglobin hydrolysate frac-
tionation by anion exchange chromatography using a Q-Se-
pharose Fast Flow gel, 177 mg of peptide fraction was ob-
tained from 2375 mg of the initial peptic hydrolysate. After
the second step of puri¢cation by preparative reverse-phase
HPLC, 37 mg of peptide powder was obtained.
Fig. 1. Analytical RP-HPLC demonstrating the purity of the K 1^23
peptide.
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The purity of the powder was then checked by analytical
RP-HPLC (Fig. 1). The chromatogram shows a single peak
corresponding to one pure peptide as assessed by the Millen-
nium software. In order to verify that the peptide obtained
was pure and corresponded to the K 1^23 peptide of bovine
hemoglobin, mass determination by MALDI-MS and frag-
mentation by ESI-MS/MS were performed. The mass spec-
trum is presented in Fig. 2 and shows that the peptide molec-
ular mass is 2236.9 Da. The fragmentation study (not shown)
indicated that its amino acid sequence corresponded to the
¢rst 23 amino acids in the N-terminus of the bovine hemo-
globin K chain: 1VLSAADKGNVKAAWGKVGGHAAE23.
Furthermore, the theoretical pI value is 9.86, calculated by
the pI/Mw program of ExPASy (http://www.expasy.ch). This
value indicated that the peptide is positively charged at pH
7.0.
3.2. Antibacterial activity
The antibacterial activity of the K 1^23 peptide was tested
in a liquid growth assay against M. luteus strain A270.
Growth inhibition of the microbial cells occurred at a concen-
tration of 1.5 mg/ml (671 WM), a concentration corresponding
to the MIC. The initial population was 1U106 CFU/ml and
after 24 h contact with the peptide, the population was 1U105
CFU/ml in the tube corresponding to the MIC. This result
indicates a low bactericidal e¡ect of the peptide at this con-
centration. Furthermore, when the cell population of the MIC
tube was determined, a 72 h incubation of Petri plates was
necessary to obtain colonies instead of 24 h for native cells. As
many antibacterial peptides act on the permeabilization of the
cellular membrane [26], this growth delay on Petri plates of
cells previously in contact with the peptide could be due to
previous membrane perturbations caused by this peptide.
Recently, the antimicrobial activity of a bovine hemoglobin
fragment was described in the gut of the tick B. microplus [12].
This fragment, naturally present in the tick, was probably
produced by enzymatic cleavage of bovine hemoglobin inside
the tick gut. This peptide was active against Gram-positive
strains including M. luteus A270 and against fungal strains.
Its MIC against M. luteus A270 was 5 WM, a much lower
value than the one obtained with the K 1^23 peptide (670
WM). Nevertheless, the K 33^61 peptide has never been ob-
tained in vitro by enzymatic cleavage.
Although the K 1^23 peptide presents low antibacterial ac-
tivity compared to other peptides, this is the ¢rst report of an
antibacterial peptide obtained by in vitro proteolysis of bovine
hemoglobin. The mechanism of action of this peptide is prob-
ably cellular membrane perturbation leading to growth inhi-
bition of M. luteus strain A270.
3.3. Hemolytic assay
The hemolytic activity of the K 1^23 peptide was tested
towards bovine erythrocytes. Peptide concentrations of
0.671^3.355 mM were tested. The highest concentration cor-
responded to ¢ve times the MIC against M. luteus A270. No
hemolysis of erythrocytes was observed with peptide concen-
trations up to 2.013 mM, a value corresponding to three times
the MIC. On the other hand, 11% and 54% hemolysis were
observed with peptide concentrations corresponding to four
and ¢ve times the MIC, respectively. Thus, although the MIC
against M. luteus A270 was 0.671 mM, this high concentra-
tion did not induce lysis of erythrocytes. These results also
indicate that the K 1^23 peptide would be non-toxic when
used at concentrations lower than 2 mM (three times higher
than the MIC), a very high concentration for a peptide.
3.4. Interaction with liposomes and structure of the peptide in
solution
To determine if the antibacterial activity of a peptide is due
to interaction with cellular membranes, the ability of the pep-
tide to interact with and to disrupt liposomes was studied [26].
Carboxy£uorescein leakage from liposomes induced by the K
Fig. 2. Mass spectrometry analysis of K 1^23 peptide by MALDI-
MS.
Fig. 3. Time course of carboxy£uorescein leakage from liposomes
induced by three concentrations of the K 1^23 peptide. 8 : 25 WM;
F : 37.5 WM; R : 50 WM. The PDL induced by the peptides was
evaluated using the equation PDL = [(F3F0)/(Ft3F0)]U100, where F
is the £uorescence intensity after the addition of the peptides, and
F0 and Ft, respectively, the £uorescence intensity without the pep-
tides and after addition of Triton X-100 (2 g/l). Triton X-100 was
used to completely release the dye from the liposomes (100% dye
leakage).
Fig. 4. Relation between absorbance (280 nm) and K 1^23 peptide
concentrations in ammonium acetate bu¡er (10 mM; pH 7.0).
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1^23 peptide at three di¡erent concentrations was observed
(Fig. 3). The lytic activity of the peptide increased with the
concentration to reach 16% leakage at a peptide concentration
of 50 WM. This result indicates an interaction between the
peptide and liposomes which are structures mimicking bacte-
rial membranes. This interaction with the cellular membranes
of the target cells could cause modi¢cations of membrane
permeability which can lead to cellular lysis [27,28].
The lytic activity towards the liposomes was weak when
compared to natural antibacterial peptides such as melittin
which causes at least 80% leakage at a concentration of 100
WM [29]. Nevertheless, such a low result of leakage has al-
ready been observed with another biological peptide [30] and
this result is in concordance with the high value of the MIC
against M. luteus strain A270, indicating a low antibacterial
activity of the peptide in liquid growth assay.
The relationship between the concentrations of the peptide
and the absorbances observed at 280 nm is shown in Fig. 4.
The linearity of this relationship lets us suppose that the pep-
tide is present in a unique form. Moreover, exclusion chro-
matography was performed and the mass obtained for the
peptide was approximately 2200 Da (not shown). As the exact
mass of the K 1^23 peptide is 2236 Da, the peptide is a unique
and monomeric form even at concentrations as high as 10
mg/ml in ammonium acetate bu¡er (10 mM, pH 7). These
results obtained by spectrometry and gel ¢ltration indicated
that the K 1^23 peptide presents a low propensity to aggregate
in aqueous solution.
The structure in solution of the K 1^23 peptide was then
studied by infrared spectroscopy to estimate its secondary
structure. The results are presented in Table 1. The K-helical
content of the K 1^23 peptide was approximately 20%, which
means a low K-helical structuring in comparison to its K-hel-
ical content in hemoglobin which is 87% as observed with the
Rasmol software. This 20% K-helical content is also slightly
weaker but comparable to the average value of 30% K-helical
content obtained with di¡erent mathematical models from the
Network Protein Sequence analysis internet server of the Po“le
Bio-informatique Lyonnais (http://pbil.ibcp.fr). Furthermore,
these di¡erent models indicate a central position of the K-helix
for the K 1^23 peptide. As it is partially K-helically structured
in ammonium acetate bu¡er (10 mM, pH 7.0) and also
K-helically structured when integrated in bovine hemoglobin,
it could be supposed that this peptide would contain a higher
K-helical structure than 20 or 30% in an environment mimick-
ing lipid bilayer. Indeed, many antibacterial peptides adopt a
random structure in aqueous solution but a mainly K-helical
conformation in dodecylphosphocholine or in SDS micelles
[31]. This K-helical conformation of antibacterial peptides is
essential with regard to their mechanism of action towards
the microorganisms. Moreover, many antimicrobial peptides
present a high pI value. Then, by adopting an K-helical struc-
ture, interactions between positively charged peptides and the
cellular membranes lead to the formation of channels or pores
within the microbial membrane to permeate the cell and im-
pair its ability to carry out metabolic processes [32]. As the K
1^23 fragment is amphiphilic, K-helically structured and pos-
itively charged at pH 7.0, this peptide possesses many physico-
chemical properties of antibacterial peptides.
This peptide, easily puri¢ed by a two-step puri¢cation pro-
cess including anion exchange chromatography and prepara-
tive RP-HPLC, can be obtained in a relatively high quantity
in this way. Furthermore, this soluble peptide could be used at
concentrations at least three times the MIC against M. luteus
strain A270. In the current context of food safety and food
protection by means of natural products, use of antibacterial
peptides derived from agricultural proteins would be a rele-
vant challenge.
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